I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Gentle Laser Treatment to Lower Eye Pressure
Understanding Transscleral Diode Laser Treatment
Transscleral diode laser therapy (a type of laser that passes through the white outer wall of the eye, called the sclera) is a specialized treatment used to lower pressure inside the eye. When fluid builds up and creates elevated intraocular pressure (the force of fluid pressing against the inner walls of the eye), it can damage the optic nerve. This laser works by gently targeting the ciliary body (the small structure behind the iris that produces eye fluid) to reduce fluid production and bring pressure down to safer levels.
Unlike traditional laser treatments that use continuous energy, the non-thermal micropulse version of this laser delivers energy in tiny, rapid bursts. These short pulses allow the tissue to cool between each burst. This approach helps protect surrounding structures while still achieving the desired pressure-lowering effect.
Older forms of transscleral laser treatment used a continuous beam of energy. While effective at lowering eye pressure, continuous-wave laser carried a higher risk of damaging nearby tissues. The micropulse approach represents a significant advancement. A peer-reviewed comparison found that micropulse transscleral laser treatment had a significantly lower complication rate than continuous-wave treatment (Nature Eye, 2024).
The non-thermal approach means the laser does not rely on heat-based tissue destruction. Instead, it stimulates a biological response within the ciliary body cells. This allows the treatment to reduce fluid production without causing the level of structural damage associated with older techniques.
Your retina specialist or glaucoma specialist may recommend this procedure if eye pressure remains elevated despite medications or other treatments. It is frequently used for people with refractory glaucoma (glaucoma that has not responded well to standard therapies). It may also help patients who have difficulty using multiple eye drop medications each day.
This treatment has been studied in several types of glaucoma, including primary open-angle glaucoma, secondary glaucoma, and neovascular glaucoma (a form of glaucoma caused by abnormal blood vessel growth). Your eye specialist will determine whether this approach is appropriate based on your specific condition and treatment history.
How the Procedure Works
Your eye specialist will perform a thorough examination before scheduling the procedure. This typically includes measuring your baseline eye pressure, evaluating the health of your optic nerve, and reviewing your current medications. You will receive specific instructions about which medications to continue or pause before treatment.
On the day of the procedure, numbing drops and a local anesthetic injection (a small amount of medication placed near the eye to block pain signals) are applied to keep you comfortable. Some patients also receive mild sedation to help them relax during the session.
The procedure is performed in an outpatient setting, meaning you go home the same day. Your specialist places a specially designed probe against the outer surface of your eye. The probe delivers micropulse laser energy through the sclera to reach the ciliary body underneath.
The laser probe is moved in a slow, sweeping motion across the treatment area. Each session typically lasts several minutes depending on the energy protocol your specialist selects. You may feel mild pressure from the probe, but the numbing medication helps minimize discomfort. The non-thermal nature of the micropulse delivery helps reduce the sensation compared to older continuous-wave approaches.
Micropulse technology works by dividing the continuous laser beam into a series of very brief 'on' periods separated by longer 'off' periods. This pattern is called the duty cycle (the percentage of time the laser is actively firing during each cycle). A lower duty cycle means longer rest periods between pulses, giving tissue more time to cool.
Research has shown that subliminal (below the threshold of visible tissue damage) energy delivery can effectively lower eye pressure while preserving tissue structure (International Journal of Ophthalmology and Clinical Research, 2022). This represents a fundamentally different approach from treatments that rely on destroying tissue to achieve their effect.
What to Expect After Treatment
After the procedure, your eye may feel mildly sore or irritated. Your specialist will typically prescribe anti-inflammatory eye drops to manage any swelling. Most patients notice these symptoms improve within the first few days. You will likely have a follow-up appointment within the first week so your specialist can check your eye pressure and look for any early signs of inflammation.
It is normal for eye pressure to fluctuate in the days following treatment. The full pressure-lowering effect may take several weeks to become apparent. Your specialist will monitor your progress and adjust your medication regimen as needed during this recovery period.
Most people can return to light daily activities within a day or two. Your specialist may advise you to avoid heavy lifting, strenuous exercise, or rubbing your eye for a short period after treatment. Driving should be avoided until your specialist confirms that your vision has stabilized enough for safe operation of a vehicle.
You will likely continue using some or all of your current eye pressure medications during the initial recovery period. As the treatment effect becomes established, your specialist may gradually reduce the number of medications you need.
Regular monitoring is essential after this procedure. Your specialist will schedule periodic check-ups to measure eye pressure, assess optic nerve health, and evaluate whether additional treatment sessions may be needed. A five-year study of micropulse transscleral treatment found that approximately 38 percent of treated eyes required retreatment over the follow-up period (Ophthalmology and Therapy, 2024).
This means that while many patients achieve lasting pressure reduction from a single session, some may benefit from additional treatments over time. Your specialist will discuss the appropriate follow-up schedule based on your individual response.
Effectiveness and Research Findings
Clinical research has demonstrated meaningful eye pressure reduction with micropulse transscleral diode laser treatment. A landmark five-year study found that patients with primary glaucoma experienced progressive pressure reduction, with mean eye pressure decreasing by approximately 37 percent from baseline at the five-year follow-up point (Ophthalmology and Therapy, 2024). These results suggest that the pressure-lowering benefit may be sustained and may even improve over several years.
Shorter-term studies have also shown positive results. Research in a Japanese population found that mean eye pressure decreased from approximately 23 mmHg before treatment to approximately 15 mmHg at six months, representing a substantial reduction (Journal of Clinical Medicine, 2024). These findings are consistent across multiple study populations worldwide.
One meaningful benefit for many patients is the potential to reduce the number of daily eye drop medications. Managing multiple eye drops each day can be challenging, and reducing this burden can improve quality of life. Research has shown that subliminal laser treatment reduced at least one topical eye pressure medication in 60 percent of patients (BMC Ophthalmology, 2024).
Fewer daily medications can also mean fewer side effects from the drops themselves. Some glaucoma medications cause redness, stinging, or other local irritation. Reducing the medication burden through effective laser treatment can provide relief from these ongoing side effects.
When compared directly to continuous-wave transscleral laser, the micropulse approach achieves similar pressure-lowering results with a more favorable safety profile. A comparative study found that at 12 months, the micropulse group achieved a mean pressure decrease from approximately 26 mmHg to approximately 17 mmHg, with no significant changes observed in visual acuity or corneal cell counts (Nature Eye, 2024). This stability in other eye health measures is an important advantage.
Your specialist may also consider other treatment options, including surgical interventions or drainage devices. The micropulse transscleral approach is frequently considered as a less invasive alternative or as a complementary treatment alongside other strategies.
Safety and Potential Side Effects
As with any medical procedure, there are potential side effects to be aware of. The most commonly reported effects include mild inflammation inside the eye, temporary blurred vision, and mild discomfort in the treated eye. These effects are typically manageable with prescribed anti-inflammatory eye drops and tend to resolve within the first few weeks.
Some patients experience a temporary fluctuation in eye pressure following treatment. Your specialist will monitor this closely during your follow-up visits. Mild redness or swelling of the eye surface is also possible and usually resolves without additional intervention.
More significant complications are uncommon with the micropulse approach. A study of micropulse transscleral treatment found that hypotony (abnormally low eye pressure) occurred in fewer than two percent of treated eyes (Ophthalmology Glaucoma, 2020). Prolonged inflammation lasting more than three months was observed in a smaller subset of patients in some studies.
Pupillary changes, such as mild dilation of the pupil on the treated side, have been reported in approximately five percent of patients in one study group (Nature Eye, 2024). Serious complications such as phthisis bulbi (shrinking of the eye), corneal decompensation, or severe vision loss are rare with the micropulse technique and are more commonly associated with older continuous-wave approaches.
You should contact your eye specialist promptly if you experience a sudden decrease in vision, severe pain that does not respond to prescribed medications, or increasing redness and discharge from the treated eye. These symptoms could indicate a complication that needs prompt attention.
It is also important to keep all scheduled follow-up appointments, even if your eye feels comfortable. Some changes in eye pressure or internal inflammation may not cause noticeable symptoms but still require professional evaluation. Never ignore sudden changes in your vision, and always follow your specialist's instructions regarding medication use and activity restrictions.
Conditions Treated with This Approach
The most common application of micropulse transscleral diode laser is for open-angle glaucoma (the most common type, where the eye's drainage angle remains open but fluid does not drain efficiently) that has not responded adequately to medications or prior surgical interventions. For these patients, the non-thermal laser provides an additional treatment option that avoids the risks of more invasive surgical procedures.
Studies have shown positive outcomes specifically in primary open-angle glaucoma populations. The treatment can be repeated if needed, giving your specialist flexibility in managing your condition over time.
Neovascular glaucoma occurs when abnormal blood vessels grow over the eye's drainage structures, blocking fluid outflow. This condition is frequently seen in patients with advanced diabetic retinopathy (damage to the blood vessels of the retina caused by diabetes) or retinal vein occlusion (a blockage of blood vessels in the retina). Transscleral diode laser has been used in these challenging cases to help control eye pressure.
Research has shown that the probability of treatment success at 36 months was approximately 56 percent in neovascular glaucoma patients (Journal of Glaucoma, 2024). While this success rate is lower than in other glaucoma types, the treatment still provides a valuable option for patients with this difficult-to-manage condition. Your specialist may combine this laser treatment with intravitreal injections (medications placed directly into the eye) to address both the pressure and the underlying blood vessel abnormalities.
Secondary glaucoma refers to elevated eye pressure caused by another condition, such as inflammation, trauma, or prior eye surgery. The micropulse approach has shown effectiveness in these varied situations. Because it is less destructive than traditional cyclodestructive procedures, it may be considered earlier in the treatment course for certain patients.
In younger patients or those with developmental forms of glaucoma, the non-thermal approach may provide advantages due to its tissue-sparing properties. Your specialist will carefully weigh the potential benefits against other available treatment options when developing a treatment plan.
Preparing for Your Appointment
Before proceeding with treatment, you may find it helpful to discuss several key points with your eye specialist. Consider asking about the expected degree of pressure reduction based on your specific type of glaucoma. Ask about the likelihood of needing retreatment and what the typical timeline for follow-up visits looks like.
You may also want to ask about how this treatment fits into your overall glaucoma management plan. Understanding whether the laser is intended to replace medications, supplement them, or serve as a bridge to another procedure can help you feel more informed about your care.
On the day of treatment, bring a current list of all medications you are taking, including eye drops. Arrange for someone to drive you home after the procedure, as your vision may be temporarily affected by the numbing medication and the treatment itself.
Wear comfortable clothing and plan for the visit to take one to two hours, including preparation time, the procedure itself, and a brief observation period afterward. Your specialist's team will provide specific pre-procedure instructions, which may include guidance on eating, drinking, and medication timing on the day of treatment.
Frequently Asked Questions
Research suggests that the pressure-lowering benefit can be sustained for several years. A five-year study showed progressive pressure reduction that was maintained throughout the follow-up period (Ophthalmology and Therapy, 2024). However, individual results vary, and some patients may need additional treatment sessions over time. Your specialist will monitor your response and recommend retreatment if your pressure begins to rise again.
Yes, one of the advantages of the micropulse non-thermal approach is that it can be repeated. Because it does not cause significant structural destruction of the ciliary body, additional sessions can be performed if the initial treatment effect diminishes over time. Your specialist will determine the appropriate timing and energy settings for any repeat treatments based on your individual response.
Many patients continue using some medications after treatment, at least initially. Over time, your specialist may be able to reduce the number of drops you use. Studies have shown that a meaningful proportion of patients are able to reduce their medication burden following this procedure. Your specialist will guide any changes to your medication regimen based on your post-treatment eye pressure measurements.
This laser treatment has been studied in several types of glaucoma, including primary open-angle, secondary, and neovascular glaucoma. However, the effectiveness may vary depending on the type and severity of your condition. Your specialist will evaluate whether this approach is the best option for your specific situation, taking into account your overall eye health, prior treatments, and treatment goals.
Traditional continuous-wave transscleral laser uses sustained energy that creates thermal (heat-based) tissue destruction. The micropulse non-thermal approach delivers energy in very short bursts with rest periods in between, allowing tissue to cool and reducing the risk of collateral damage. Research has shown that the micropulse method achieves similar pressure reduction with a significantly lower complication rate compared to the continuous-wave technique (Nature Eye, 2024).
30 Years of Care & Commitment
